Under the terms of the agreement, Pfizer will pay Genizon upfront license fees and funding for research on genetic variations associated with diseases. Pfizer will also purchase an equity stake in Genizon subject to certain closing conditions. Financial terms were not disclosed.
The collaboration involves discovery of diagnostic markers from three ongoing genome-wide association studies using Genizon's proprietary technology platform. The collaboration will expand these discoveries by including results with those from genome-wide association studies from general populations.
“We expect the results of this research to lead to earlier and more accurate diagnosis and improved health care for patients afflicted with Alzheimer's disease, ADHD and endometriosis,” said Dr John Hooper, president and CEO of Genizon BioSciences.